AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35043976
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MCT4 inhibition and anti-PD-1 immunotherapy
Trial: 35045184
Drug: Hyperglycemia and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia and higher insulin doses
Trial: 35045358
Drug: Intravenous CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CAR T cells administered intrapleurally (10-186 mL) via image-guided techniques (intracavitary or intratumoral)
Trial: 35045358
Drug: Intravenous CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CAR T cells administered intrapleurally
Trial: 35045815
Drug: Various palliative
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various palliative interventions for ESCC including chemotherapy, radiation therapy (with and without chemotherapy), and esophageal stenting with self-expandable metallic stents.
Trial: 35045989
Drug: Remdesivir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days)
Trial: 35046056
Drug: VIP152 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP152 monotherapy (30 mg, once-weekly intravenous infusion)
Trial: 35046132
Drug: Steroid-sparing immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-sparing immunosuppressive protocol
Trial: 35046132
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of mineral metabolism
Trial: 35046747
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation (five 30-minute weekly sessions)
Trial: 35046880
Drug: Oral mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mannitol (18 g per day)
Trial: 35047784
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy after revascularisation
Trial: 35050753
Drug: Molecular-based recommended
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular-based recommended therapy (MBRT)
Trial: 35050753
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies provided in the setting of a clinical trial or through compassionate use programs
Trial: 35050961
Drug: Interdisciplinary multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary multimodal pain therapy
Trial: 35051703
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (cCRT) with trametinib (1.5 mg)
Trial: 35051950
Drug: Severe intraoperative
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe intraoperative hyperglycemia (SIH) with blood glucose concentration (BGC) ≥180 mg/dL
Trial: 35051950
Drug: No severe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No severe intraoperative hyperglycemia (BGC <180 mg/dL)
Trial: 35051950
Drug: Intraoperative BGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative BGC >140 mg/dL
Trial: 35058275
Drug: Non-curative ESD
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-curative ESD followed by surgical treatment (n=126)
Trial: 35058326
Drug: isatuximab (anti-CD38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isatuximab (anti-CD38 monoclonal antibody) + cemiplimab (anti-PD-1 monoclonal antibody)
Trial: 35059291
Drug: Nonsurgical traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical traditional Korean medical treatment
Trial: 35060907
Drug: InTSHA intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: InTSHA intervention (mobile phone-based intervention using WhatsApp, 10 modules conducted weekly)
Trial: 35060914
Drug: Microbial Ecosystem
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial Ecosystem Therapeutic-2 (MET-2), 3 capsules per day for 8 weeks
Trial: 35061769
Drug: Hypertension (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension (defined as known hypertension or use of antihypertensive medication)
Trial: 35062926
Drug: Fruit and
RxNorm normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit and Vegetable Prescription Program (FVPP) with high exposure (> 24 months)
Trial: 35062926
Drug: Fruit and
RxNorm normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit and Vegetable Prescription Program (FVPP) with moderate exposure (12-24 months)
Trial: 35062926
Drug: Fruit and
RxNorm normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit and Vegetable Prescription Program (FVPP) with no previous exposure
Trial: 35062987
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C supplementation (40 mg/kg)
Trial: 35063276
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance monotherapy (300 mg twice daily)
Trial: 35064011
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A1, dMMR/MSI-H)
Trial: 35064011
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A2, MMRp/MSS)
Trial: 35065058
Drug: Neoadjuvant cemiplimab
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks for 2 cycles followed by surgical resection.
Trial: 35065599
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 0.2 mg/kg of cisatracurium
Trial: 35065785
Drug: arsa-cel (gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arsa-cel (gene therapy)
Trial: 35066531
Drug: Dual-source photon-counting
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-source photon-counting detector computed tomography (PCD-CT) with late enhancement (LE) scan using 100 mL contrast media.
Trial: 35066693
Drug: Crenolanib 100
RxNorm normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenolanib 100 mg BID with paclitaxel 80 mg/m² and ramucirumab
Trial: 35067072
Drug: Intracoronary CD34+
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary CD34+ cell therapy
Trial: 35067230
Drug: Vigabatrin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (single loading dose of 4500 mg via enteric tube within 48 h of PASE onset)
Trial: 35067596
Drug: Phone-delivered mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phone-delivered mindfulness training (MT) for 30 minutes weekly for 8 weeks
Trial: 35067748
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in antibiotic treatment
Trial: 35067817
Drug: Non-ablative Er:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ablative Er:YAG laser treatment (IncontiLase® procedure)
Trial: 35067817
Drug: Single-session maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session maintenance treatments every 6 months
Trial: 35067817
Drug: Non-ablative Er:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ablative Er:YAG laser treatment
Trial: 35067914
Drug: Steroid treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment, specific dosage and duration not available
Trial: 35068788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of autologous HSC and MSC infusion
Trial: 35068788
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) administration
Trial: 35070795
Drug: PDE-5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE-5 inhibitors
Trial: 35070991
Drug: Citarinostat 360
RxNorm normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citarinostat 360 mg once daily plus paclitaxel 80 mg/m²
Trial: 35070991
Drug: Citarinostat 480
RxNorm normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citarinostat 480 mg once daily plus paclitaxel 80 mg/m²
Trial: 35070991
Drug: Citarinostat 180
RxNorm normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citarinostat 180 mg once daily plus paclitaxel 80 mg/m²
Trial: 35071653
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (24 patients)
Trial: 35071653
Drug: Medium-dose group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose group (25 patients)
Trial: 35071653
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (24 patients)
Trial: 35072135
Drug: Chronic RASI
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic RASI therapy
Trial: 35072135
Drug: In-hospital RASI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital RASI therapy
Trial: 35072168
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg maintenance weeks 0/4/16/28/40
Trial: 35073853
Drug: COVID-19 antigen
RxNorm normalized name: COVID-19 antigen vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 antigen and antibody associations
Trial: 35073963
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) prescribed based on pattern differentiation in addition to conventional medication (ConM)
Trial: 35073963
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication (ConM) only
Trial: 35074020
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet (840 kcal/day) for weight loss and diabetes remission, 12-week duration, monitored weekly for weight and blood glucose.
Trial: 35074072
Drug: Ibrutinib-rituximab induction
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib-rituximab induction (12 cycles; oral ibrutinib 560 mg daily and intravenous rituximab 375 mg/m2)
Trial: 35074072
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment approach (ibrutinib-rituximab followed by R-HCVAD)
Trial: 35075450
Drug: mRNA BNT162b2
RxNorm normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA BNT162b2 vaccine (two doses)
Trial: 35076282
Drug: AZD7442 (300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (300-mg intramuscular injection)
Trial: 35076282
Drug: AZD7442 (prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (prophylactic administration)
Trial: 35076282
Drug: AZD7442 (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (therapeutic administration)
Trial: 35076703
Drug: Vamorolone (≥2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamorolone (≥2.0 mg/kg/d)
Trial: 35076931
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg intravenous dose
Trial: 35078538
Drug: Transcutaneous auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous auricular vagus nerve stimulation (taVNS) for five minutes daily for 26 weeks.
Trial: 35078739
Drug: Selinexor 60mg
RxNorm normalized name: SELINEXOR 60MG WEEKLY PKT
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor 60mg twice weekly
Trial: 35079784
Drug: INO-4800 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg)
Trial: 35079784
Drug: INO-4800 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-4800 (2.0 mg)
Trial: 35080076
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for sinonasal malignancies
Trial: 35081106
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment for school attendance problems (SAPs)
Trial: 35081293
Drug: mRNA-1273 (Moderna)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (Moderna) at a dose of 100 μg
Trial: 35081293
Drug: Ad26.COV2.S (Johnson
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×10^10 viral particles
Trial: 35081550
Drug: Herbal/dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal/dietary supplements (HDS)
Trial: 35081732
Drug: Inactive SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive SARS-CoV-2 vaccination (inactivated virus vaccine)
Trial: 35082572
Drug: LAR subtype
RxNorm normalized name: Influenza A virus subtype H3N2 haemagglutinin, recombinant
DrugBank: Influenza A virus subtype H3N2 haemagglutinin, recombinant (DB16642)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAR subtype after standard adjuvant or neoadjuvant chemotherapy
Trial: 35082572
Drug: Non-LAR disease
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LAR disease after standard adjuvant or neoadjuvant chemotherapy
Trial: 35083234
Drug: Intracameral conbercept
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral conbercept injection
Trial: 35083365
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine
Trial: 35084435
Drug: BQ-788 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-788 (selective ETB antagonist)
Trial: 35084584
Drug: Dental implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implants placed in patients on HDAR (bisphosphonates and denosumab)
Trial: 35084584
Drug: Abutment operation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abutment operation performed 4 months after implant placement
Trial: 35085462
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) administered to 15 patients
Trial: 35086123
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of LPC16:0
Trial: 35086148
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitors (AIs)
Trial: 35086481
Drug: Direct antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct antiviral agents
Trial: 35086504
Drug: Customized adherence
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized adherence enhancement intervention combined with long-acting injectable antipsychotic medication (LAI)
Trial: 35086504
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable antipsychotic medication (LAI)
Trial: 35086949
Drug: Curative-intent dose-dense
RxNorm normalized name: CUR-1916
DrugBank: CUR-1916 (DB17838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative-intent dose-dense anthracycline and cyclophosphamide (ddAC)
Trial: 35087084
Drug: Early booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early booster Vi-DT vaccine
Trial: 35087084
Drug: Late booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late booster Vi-DT vaccine
Trial: 35087595
Drug: Heat-clearing Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-clearing Traditional Chinese Medicine (TCM) individualized decoction
Trial: 35087595
Drug: Control (individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (individualized decoction without heat-clearing drugs)
Trial: 35088348
Drug: Nemolizumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab (60 mg loading dose at baseline, followed by 30 mg every 4 weeks until week 12) with background topical corticosteroids or calcineurin inhibitors.
Trial: 35088348
Drug: Nemolizumab treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab treatment.
Trial: 35088735
Drug: Intraoperative neuromonitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative neuromonitoring with evoked compound action potentials (ECAP) and late response (LR) recording
Trial: 35089449
Drug: Digital Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Pill System (DPS) for measuring PrEP adherence
Trial: 35090035
Drug: Intravenous contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous contrast agent administration
Trial: 35090035
Drug: Intra-arterial contrast
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial contrast agent administration
Trial: 35091443
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 1 (prior radiotherapy/ALKi-pretreated)
Trial: 35091443
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 2 (no radiotherapy/ALKi-pretreated)
Trial: 35091443
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 3 (prior radiotherapy/ALKi-naïve)
Trial: 35091443
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 4 (no radiotherapy/ALKi-naïve)
Trial: 35091443
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 5 (patients with leptomeningeal carcinomatosis)
Trial: 35091462
Drug: Biological disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological disease-modifying drugs
Trial: 35091711
Drug: Apalutamide 240
RxNorm normalized name: apalutamide 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide 240 mg once-daily for 12 weeks
Trial: 35092583
Drug: AMG 986
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 986 200 mg
Trial: 35093104
Drug: Audit-and-feedback intervention
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audit-and-feedback intervention including reports on antibiotic harms, stakeholder engagement, patient and provider education, identification of local champions, and blended facilitation.
Trial: 35093147
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) for fetuses with LSDs